A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Cancer Cell

Volumn 28, Issue 1, 2015, Pages 57-69

  Mohammad, HelaiP ^a   Smitheman, KimberlyN ^a   Kamat, ChandrashekharD ^b   Soong, David ^a   Federowicz, KellyE ^a   VanAller, GlennS ^a   Schneck, JessL ^a   Carson, JeffreyD ^a   Liu, Yan ^a   Butticello, Michael ^a   Bonnette, WilliamG ^a   Gorman, ShelbyA ^a   Degenhardt, Yan ^a   Bai, Yuchen ^a   McCabe, MichaelT ^a   Pappalardi, MelissaB ^a   Kasparec, Jiri ^a   Tian, Xinrong ^a   McNulty, KennethC ^a   Rouse, Meagan ^a   McDevitt, Patrick ^a   Ho, Thau ^a   Crouthamel, Michelle ^a   Hart, TimothyK ^a   Concha, NestorO ^a   McHugh, CharlesF ^a   Miller, WilliamH ^a   Dhanak, Dashyant ^a   Tummino, PeterJ ^a   Carpenter, ChristopherL ^a   Johnson, NeilW ^a   Hann, ChristineL ^b   Kruger, RyanG ^a   more..

^a GLAXOSMITHKLINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GSK 2879552; HISTONE DEMETHYLASE; LYSINE DEMETHYLASE 1; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE; CYCLOPROPANE DERIVATIVE; ENZYME INHIBITOR; GSK2879552; KDM1A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; DNA METHYLATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMALL CELL LUNG CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LUNG NEOPLASMS; MOLECULAR GENETICS; ORAL DRUG ADMINISTRATION; PATHOLOGY; SMALL CELL LUNG CARCINOMA; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOATES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOPROPANES; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEMETHYLASES; HUMANS; LUNG NEOPLASMS; MICE; MOLECULAR SEQUENCE DATA; SMALL CELL LUNG CARCINOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937429405     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.06.002     Document Type: Article

References (47)

1. Adamo A., Barrero M.J., Izpisua Belmonte J.C. LSD1 and pluripotency: a new player in the network. Cell Cycle 2011, 10:3215-3216.
2. Adamo A., Sesé B., Boue S., Castaño J., Paramonov I., Barrero M.J., Izpisua Belmonte J.C. LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells. Nat. Cell Biol. 2011, 13:652-659.
3. Baker G.B., Coutts R.T., McKenna K.F., Sherry-McKenna R.L. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J.Psychiatry Neurosci. 1992, 17:206-214.
4. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
5. Bernstein B.E., Kamal M., Lindblad-Toh K., Bekiranov S., Bailey D.K., Huebert D.J., McMahon S., Karlsson E.K., Kulbokas E.J., Gingeras T.R., et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 2005, 120:169-181.
6. Binda C., Valente S., Romanenghi M., Pilotto S., Cirilli R., Karytinos A., Ciossani G., Botrugno O.A., Forneris F., Tardugno M., et al. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J.Am. Chem. Soc. 2010, 132:6827-6833.
7. Copeland R.A., Moyer M.P., Richon V.M. Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene 2013, 32:939-946.
8. Daigle S.R., Olhava E.J., Therkelsen C.A., Basavapathruni A., Jin L., Boriack-Sjodin P.A., Allain C.J., Klaus C.R., Raimondi A., Scott M.P., et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013, 122:1017-1025.
9. Daniel V.C., Marchionni L., Hierman J.S., Rhodes J.T., Devereux W.L., Rudin C.M., Yung R., Parmigiani G., Dorsch M., Peacock C.D., Watkins D.N. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture invitro. Cancer Res. 2009, 69:3364-3373.
10. Harris W.J., Huang X., Lynch J.T., Spencer G.J., Hitchin J.R., Li Y., Ciceri F., Blaser J.G., Greystoke B.F., Jordan A.M., et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21:473-487.
11. Helin K., Dhanak D. Chromatin proteins and modifications as drug targets. Nature 2013, 502:480-488.
12. Hnisz D., Abraham B.J., Lee T.I., Lau A., Saint-André V., Sigova A.A., Hoke H.A., Young R.A. Super-enhancers in the control of cell identity and disease. Cell 2013, 155:934-947.
13. Ischenko I., Liu J., Petrenko O., Hayman M.J. Transforming growth factor-beta signaling network regulates plasticity and lineage commitment of lung cancer cells. Cell Death Differ. 2014, 21:1218-1228.
14. Johnson B.E., Russell E., Simmons A.M., Phelps R., Steinberg S.M., Ihde D.C., Gazdar A.F. MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer. J.Cell. Biochem. Suppl. 1996, 24:210-217.
15. Kahl P., Gullotti L., Heukamp L.C., Wolf S., Friedrichs N., Vorreuther R., Solleder G., Bastian P.J., Ellinger J., Metzger E., et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006, 66:11341-11347.
16. Knutson S.K., Wigle T.J., Warholic N.M., Sneeringer C.J., Allain C.J., Klaus C.R., Sacks J.D., Raimondi A., Majer C.R., Song J., et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 2012, 8:890-896.
17. Lim S., Metzger E., Schüle R., Kirfel J., Buettner R. Epigenetic regulation of cancer growth by histone demethylases. Int. J. Cancer 2010, 127:1991-1998.
18. Lv T., Yuan D., Miao X., Lv Y., Zhan P., Shen X., Song Y. Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS ONE 2012, 7:e35065.
19. Lynch J.T., Harris W.J., Somervaille T.C. LSD1 inhibition: a therapeutic strategy in cancer?. Expert Opin. Ther. Targets 2012, 16:1239-1249.
20. McCabe M.T., Ott H.M., Ganji G., Korenchuk S., Thompson C., Van Aller G.S., Liu Y., Graves A.P., Della Pietra A., Diaz E., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
21. McDonald O.G., Wu H., Timp W., Doi A., Feinberg A.P. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat. Struct. Mol. Biol. 2011, 18:867-874.
22. Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene 1999, 18:3004-3016.
23. Nørgaard P., Damstrup L., Rygaard K., Spang-Thomsen M., Skovgaard Poulsen H. Growth suppression by transforming growth factor beta 1 of human small-cell lung cancer cell lines is associated with expression of the type II receptor. Br. J. Cancer 1994, 69:802-808.
24. Park K.S., Liang M.C., Raiser D.M., Zamponi R., Roach R.R., Curtis S.J., Walton Z., Schaffer B.E., Roake C.M., Zmoos A.F., et al. Characterization of the cell of origin for small cell lung cancer. Cell Cycle 2011, 10:2806-2815.
25. Peifer M., Fernández-Cuesta L., Sos M.L., George J., Seidel D., Kasper L.H., Plenker D., Leenders F., Sun R., Zander T., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 2012, 44:1104-1110.
26. Poirier J.T., Dobromilskaya I., Moriarty W.F., Peacock C.D., Hann C.L., Rudin C.M. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. J.Natl. Cancer Inst. 2013, 105:1059-1065.
27. Radich J.P., Dai H., Mao M., Oehler V., Schelter J., Druker B., Sawyers C., Shah N., Stock W., Willman C.L., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA 2006, 103:2794-2799.
28. Rhodes D.R., Kalyana-Sundaram S., Mahavisno V., Varambally R., Yu J., Briggs B.B., Barrette T.R., Anstet M.J., Kincead-Beal C., Kulkarni P., et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007, 9:166-180.
29. Rodriguez E., Lilenbaum R.C. Small cell lung cancer: past, present, and future. Curr. Oncol. Rep. 2010, 12:327-334.
30. Rudin C.M., Durinck S., Stawiski E.W., Poirier J.T., Modrusan Z., Shames D.S., Bergbower E.A., Guan Y., Shin J., Guillory J., et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 2012, 44:1111-1116.
31. Saleque S., Kim J., Rooke H.M., Orkin S.H. Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. Mol. Cell 2007, 27:562-572.
32. Santos-Rosa H., Schneider R., Bannister A.J., Sherriff J., Bernstein B.E., Emre N.C., Schreiber S.L., Mellor J., Kouzarides T. Active genes are tri-methylated at K4 of histone H3. Nature 2002, 419:407-411.
33. Sarvi S., Mackinnon A.C., Avlonitis N., Bradley M., Rintoul R.C., Rassl D.M., Wang W., Forbes S.J., Gregory C.D., Sethi T. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res. 2014, 74:1554-1565.
34. Schenk T., Chen W.C., Göllner S., Howell L., Jin L., Hebestreit K., Klein H.U., Popescu A.C., Burnett A., Mills K., et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 2012, 18:605-611.
35. Schmidt D.M., McCafferty D.G. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 2007, 46:4408-4416.
36. Serce N., Gnatzy A., Steiner S., Lorenzen H., Kirfel J., Buettner R. Elevated expression of LSD1 (lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast. BMC Clin. Pathol. 2012, 12:13.
37. Sgambato A., Casaluce F., Maione P., Rossi A., Sacco P.C., Panzone F., Ciardiello F., Gridelli C. Medical treatment of small cell lung cancer: state of the art and new development. Expert Opin. Pharmacother. 2013, 14:2019-2031.
38. Shi Y., Sawada J., Sui G., Affar B., Whetstine J.R., Lan F., Ogawa H., Luke M.P., Nakatani Y., Shi Y. Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 2003, 422:735-738.
39. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J.R., Cole P.A., Casero R.A., Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119:941-953.
40. Sprüssel A., Schulte J.H., Weber S., Necke M., Händschke K., Thor T., Pajtler K.W., Schramm A., König K., Diehl L., et al. Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia 2012, 26:2039-2051.
41. Sumitomo K., Kurisaki A., Yamakawa N., Tsuchida K., Shimizu E., Sone S., Sugino H. Expression of a TGF-beta1 inducible gene, TSC-36, causes growth inhibition in human lung cancer cell lines. Cancer Lett. 2000, 155:37-46.
42. Wang J., Hevi S., Kurash J.K., Lei H., Gay F., Bajko J., Su H., Sun W., Chang H., Xu G., et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet. 2009, 41:125-129.
43. Wang Y., Zhang H., Chen Y., Sun Y., Yang F., Yu W., Liang J., Sun L., Yang X., Shi L., et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009, 138:660-672.
44. Whyte W.A., Bilodeau S., Orlando D.A., Hoke H.A., Frampton G.M., Foster C.T., Cowley S.M., Young R.A. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature 2012, 482:221-225.
45. Wouters B.J., Löwenberg B., Erpelinck-Verschueren C.A., van Putten W.L., Valk P.J., Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009, 113:3088-3091.
46. You A., Tong J.K., Grozinger C.M., Schreiber S.L. CoREST is an integral component of the CoREST- human histone deacetylase complex. Proc. Natl. Acad. Sci. USA 2001, 98:1454-1458.
47. Zhang Z., Zhou Y., Qian H., Shao G., Lu X., Chen Q., Sun X., Chen D., Yin R., Zhu H., et al. Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells. Cell Death Dis. 2013, 4:e633.